BCOX

Biocurex Inc (BCOX) Falls Moderately On Profit Booking

 
Shares of Biocurex Inc (OTC:BCOX) are correcting marginally following a whopping 150% rally in the previous trading session after BCOX released a positive press release.
 
Yesterday, BCOX reported very impressive testing results for its RECAF blood test, which showed that the company’s development has potential to prevent 70% of unnecessary prostate biopsies.
 
In late 2010, BCOX ahd presented its product development and compared it with free-PSA, which showed 600% better than the latter’s testing to prevent unnecessary prostate biopsies.

Investors turned bullish on the stock as the BCOX’s product would be cheaper than The free-PSA blood test, which would required to pay around $100, whereas the company’s product could be available between $20 and $60.

In yesterday’s session, BCOX stock surged 150% to close at day’s high of $0.05 on hefty volume of 30.05 million shares, which was the highest one day volume at least in the past one year.

BCOX Stock Has Big Upside

This morning, BCOX stock is down 17.67% to $0.0410 with more than 10.50 million shares has already exchanged hands.

BCOX has not yet generated any revenue as of date and had a loss of $742K for the quarter ended Jun 30, 2011.

Biocurex Inc (OTC:BCOX) is a development stage company and has been working on introducing proprietary products which are related to cancer diagnostics. BCOX has already received patents for its RECAF in the United States, Europe, Australia and China and are pending in other major worldwide markets.

BCOX has market capitalization of $7.04 million. Over the past one year, BCOX stock has moved as high as $0.07 and as low as $0.01.

More Penny Stock News, IPO Updates and Stock Market Research.

Get BCOX Updates from our FREE eMail List

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.